Mesalamine derivatives in the treatment of Crohn's disease

Gastroenterology Clinics of North America

Volumn 33, Issue 2, 2004, Pages 303-317

  Harrell, Laura E ^a   Hanauer, Stephen B ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE;

ACETYLATION; ALLERGIC REACTION; ANOREXIA; ARTHRALGIA; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CROHN DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; FEVER; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS; HIGH RISK POPULATION; HUMAN; HYPERSENSITIVITY; META ANALYSIS; MYALGIA; NAUSEA; NEPHRITIS; NEPHROTOXICITY; PANCREATITIS; PNEUMONIA; RASH; REVIEW; ULCERATIVE COLITIS; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROHN DISEASE; HUMANS; MESALAMINE;

EID: 2942530847     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2004.02.010     Document Type: Review

References (80)

1. Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol. 83:1988;497-503
2. Azad Khan A.K., Piris J., Truelove S.C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 2:1977;892-895
3. Haagen Nielsen O., Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol. 16:1983;738-740
4. Myers B., et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 28:1987;196-200
5. Layer P.H., et al. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology. 108:1995;1427-1433
6. Zhou S.Y., et al. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos. 27:1999;479-485
7. Sandborn W.J., Hanauer S.B. The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 17:2003;29-42
8. Rasmussen S.N., et al. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 83:1982;1062-1070
9. Das K.M., Eastwood M.A. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease. Clin Pharmacol Ther. 18:(5 Pt 1):1975;514-520
10. Nielsen O.H. Sulfasalazine intolerance: a retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 17:1982;389-393
11. Taffet S.L., Das K.M. Sulfasalazine: adverse effects and desensitization. Dig Dis Sci. 28:1983;833-842
12. Singleton J.W., et al. National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology. 77:(4 Pt 2):1979;870-882
13. Korelitz B.I., et al. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease. J Clin Gastroenterol. 6:1984;27-31
14. Mihas A.A., Goldenberg D.J., Slaughter R.L. Sulfasalazine toxic reactions: hepatitis, fever, and skin rash with hypocomplementemia and immune complexes. JAMA. 239:1978;2590-2591
15. Callen J.P., Soderstrom R.M. Granulomatous hepatitis associated with salicylazosulfapyridine therapy. South Med J. 71:1978;1159-1160
16. Kanner R.S., Tedesco F.J., Kalser M.H. Azulfidine- (sulfasalazine-) induced hepatic injury. Am J Dig Dis. 23:1978;956-958
17. Hamadeh M.A., Atkinson J., Smith L.J. Sulfasalazine-induced pulmonary disease. Chest. 101:1992;1033-1037
18. Carr-Locke D.L. Sulfasalazine-induced lupus syndrome in a patient with Crohn's disease. Am J Gastroenterol. 77:1982;614-616
19. Davies G.E., Palek J. Selective erythroid and magakaryocytic aplasia after sulfasalazine administration. Arch Intern Med. 140:1980;1122
20. Chakraborty T.K., et al. Salicylate induced exacerbation of ulcerative colitis. Gut. 28:1987;613-615
21. Rao S.S., Cann P.A., Holdsworth C.D. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Scand J Gastroenterol. 22:1987;332-336
22. Rao S.S., Read N.W., Holdsworth C.D. Influence of olsalazine on gastrointestinal transit in ulcerative colitis. Gut. 28:1987;1474-1477
23. Pamukcu R., Hanauer S.B., Chang E.B. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro: comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology. 95:1988;975-981
24. Brouillard M., et al. Chronic interstitial nephritis and mesalazine: 3 new cases? Gastroenterol Clin Biol. 22:1998;724-726
25. Calvino J., et al. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin Nephrol. 49:1998;265-267
26. Mahmud N., et al. Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment Pharmacol Ther. 16:2002;207-215
27. Hanauer S.B., Verst-Brasch C., Regalli G. Renal safety of long-term mesalamine therapy in inflammatory bowel disease (IBD). Gastroenterology. 112:1997;A991
28. Marteau P., et al. Adverse events in patients treated with 5-aminosalicyclic acid: 1993-1994 pharmacovigilance report for Pentasa in France. Aliment Pharmacol Ther. 10:1996;949-956
29. Sutherland L.R., May G.R., Shaffer E.A. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. [see comments] Ann Intern Med. 118:1993;540-549
30. Sutherland L., et al. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis. Cochrane Database Syst Rev. 2:2000
31. Sutherland L., et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 1:2003
32. Green J.R., et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology. 114:1998;15-22
33. Levine D.S., et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 97:2002;1398-1407
34. Pruitt R., et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol. 97:2002;3078-3086
35. Sandborn W.J. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol. 97:2002;2939-2941
36. Feurle G.E., et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. Gut. 30:1989;1354-1361
37. Sutherland L., et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 1:2003
38. Gionchetti P., et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther. 13:1999;381-388
39. Cohen R.D., et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 95:2000;1263-1276
40. Marshall J.K., Irvine E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 40:1997;775-781
41. Gisbert J.P., et al. Role of 5-Aminosalicylic Acid (5-ASA) in treatment of inflammatory bowel disease. A Systematic Review. Digestive Diseases and Sciences. 47:2000;471-488
42. Mulder C.J.J., et al. A controlled randomized trial of beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (1 g) versus the combination of both as retention enemas in active distal ulcerative colitis. Gastroenterology. 106:1994;A739
43. Trallori G., et al. 5-Aminosalicylic acid enemas to maintain remission in left-sided ulcerative colitis: a meta- and economic analysis. J Clin Gastroenterol. 20:1995;257-259
44. Riley S.A. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut. 42:1998;761-763
45. Hanauer S., et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 88:1993;1188-1197
46. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 317:1987;1625-1629
47. Kruis W., et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol. 1:2003;36-43
48. d'Albasio G., et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol. 92:1997;1143-1147
49. Summers R.W., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 77:(4 Pt 2):1979;847-869
50. Malchow H., et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 86:1984;249-266
51. Singleton J.W., et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 104:1993;1293-1301
52. Hanauer S, Stromberg R. Clin Gastroenterol Hepatol, in press.
53. Saverymuttu S.H., et al. Effect of a slow-release 5′-aminosalicylic acid preparation on disease activity in Crohn's disease. Digestion. 33:1986;89-91
54. Tremaine W.J., et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol. 19:1994;278-282
55. Prantera C., et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology. 116:1999;521-526
56. Thomsen O.O., et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. [see comments] N Engl J Med. 339:1998;370-374
57. Malchow H., et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 86:1984;249-266
58. Sandborn W.J., Feagan B.G. Review article: mild to moderate Crohn's disease-defining the basis for a new treatment algorithm. Aliment Pharmacol Ther. 18:2003;263-277
59. Colombel J.F., et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol. 94:1999;674-678
60. Lennard-Jones J.E. Sulphasalazine in asymptomatic Crohn's disease: a multicentre trial. Gut. 18:1977;69-72
61. Gendre J.P., et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). [see comments] Gastroenterology. 104:1993;435-439
62. Modigliani R., et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 110:1996;688-693
63. International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group. Aliment Pharmacol Ther. 4:1990;55-64
64. Brignola C., et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci. 37:1992;29-32
65. Prantera C., et al. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology. 103:1992;363-368
66. Messori A., et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol. 89:1994;692-698
67. Steinhart A., Hemphill D., Greenberg G. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol. 89:1994;2116-2124
68. Camma C., et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 113:1997;1465-1473
69. Rutgeerts P., et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 99:1990;956-963
70. Achkar J.P., Hanauer S.B. Medical therapy to reduce postoperative Crohn's disease recurrence. Am J Gastroenterol. 95:2000;1139-1146
71. Wenckert A., et al. The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease: a controlled double-blind trial. Scand J Gastroenterol. 77:1978;847-869
72. Ewe K., et al. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion. 42:1989;224-232
73. Bergman L., Krause U. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease. Scand J Gastroenterol. 11:1976;651-656
74. Lochs H., et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology. 118:2000;264-273
75. Hanauer S.B., Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol. 96:2001;635-643
76. Steinhart A.H., et al. Corticosteroids for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2001;CD000301
77. Simms L., Steinhart A.H. Budesonide for maintenance of remission in Crohn's disease (Cochrane Review). Cochrane Database Syst Rev. 2001;1
78. Faubion W.A. Jr., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 121:2001;255-260
79. Munkholm P., et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 35:1994;360-362
80. Hanauer S.B., et al. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. [see comments] Am J Gastroenterol. 88:1993;1343-1351